1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Biosimilars

Medicare Part B Payment Boost For Biosimilars A Positive Step But ‘More Must Be Done’

 
• By Cathy Kelly

The policy is welcomed by biosimilar stakeholders, but amounts to a relatively small increase. To qualify for the revised payment, a biosimilar must have an average sales price that is less than its reference drug’s ASP and not all do.

Will an incremental payment boost Improve biosimilar Uptake In Medicare? • Source: Shutterstock

Biosimilars may see better uptake in the Medicare Part B program over the next five years if prescribers are swayed by the prospect of higher reimbursement for the follow-ons versus their reference drugs.

The Centers for Medicare and Medicaid Services launched a temporary, five-year increase in Medicare Part B reimbursement for biosimilars from average sales price plus 6% to ASP plus 8% on 1 October

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics

EU Biosimilar Filings, Opinions And Approvals

 
• By Neena Brizmohun

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Pulling Together: Global Regulators Discuss Convergence On Biosimilars

 
• By Dave Wallace

While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.